APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for the Elderly

Compare research editions
View pricing & licenses

Selected research

Industry Research

Respiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026

27 December 2025121 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for the Elderly market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Respiratory Syncytial Virus Vaccine for the Elderly market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Respiratory Syncytial Virus Vaccine for the Elderly Market by Company

GSK

Icosavax

Moderna

Pfizer

RNAimmune

Sanofi

Advaccine

Daiichi Sankyo

Immorna

Blue Lake Biotechnology

Clover Biopharma

Innorna

Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Respiratory Syncytial Virus Vaccine for the Elderly by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Respiratory Syncytial Virus Vaccine for the Elderly in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units) of Manufacturers (2021-2026) Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers (2021-2026) Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue of Manufacturers (2021-2026) Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Product Type & Application Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 22. GSK Recent Developments Table 23. Icosavax Company Information Table 24. Icosavax Business Overview Table 25. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 27. Icosavax Recent Developments Table 28. Moderna Company Information Table 29. Moderna Business Overview Table 30. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 32. Moderna Recent Developments Table 33. Pfizer Company Information Table 34. Pfizer Business Overview Table 35. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 37. Pfizer Recent Developments Table 38. RNAimmune Company Information Table 39. RNAimmune Business Overview Table 40. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 42. RNAimmune Recent Developments Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 47. Sanofi Recent Developments Table 48. Advaccine Company Information Table 49. Advaccine Business Overview Table 50. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 52. Advaccine Recent Developments Table 53. Daiichi Sankyo Company Information Table 54. Daiichi Sankyo Business Overview Table 55. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 57. Daiichi Sankyo Recent Developments Table 58. Immorna Company Information Table 59. Immorna Business Overview Table 60. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 62. Immorna Recent Developments Table 63. Blue Lake Biotechnology Company Information Table 64. Blue Lake Biotechnology Business Overview Table 65. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 67. Blue Lake Biotechnology Recent Developments Table 68. Clover Biopharma Company Information Table 69. Clover Biopharma Business Overview Table 70. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 72. Clover Biopharma Recent Developments Table 73. Innorna Company Information Table 74. Innorna Business Overview Table 75. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 77. Innorna Recent Developments Table 78. Starna Therapeutics Company Information Table 79. Starna Therapeutics Business Overview Table 80. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 82. Starna Therapeutics Recent Developments Table 83. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Units) Table 85. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026) Table 86. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032) & (Units) Table 87. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2027-2032) Table 88. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026) Table 90. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2027-2032) Table 92. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 94. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 95. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 99. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 100. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 104. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 105. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 109. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 110. South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 114. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 115. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 118. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 119. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026) Table 120. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2027-2032) Table 121. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026) Table 124. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2027-2032) Table 125. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2026) & (US$/Unit) Table 126. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2027-2032) & (US$/Unit) Table 127. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 128. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 129. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026) Table 130. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2027-2032) Table 131. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026) Table 134. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2027-2032) Table 135. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2026) & (US$/Unit) Table 136. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List Table 140. Respiratory Syncytial Virus Vaccine for the Elderly Customers List Table 141. Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends Table 142. Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers Table 143. Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Respiratory Syncytial Virus Vaccine for the Elderly Product Image Figure 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2021-2032) & (US$ Million) Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032) & (Units) Figure 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Unit) & (2021-2032) Figure 9. Recombinant Protein Vaccine Product Image Figure 10. Nucleic Acid Vaccines Product Image Figure 11. Others Product Image Figure 12. Hospital Product Image Figure 13. Centers for Disease Control and Prevention Product Image Figure 14. Others Product Image Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region in 2025 Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region in 2025 Figure 22. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country in 2025 Figure 23. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 24. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2032) Figure 25. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country in 2025 Figure 29. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 30. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2032) Figure 31. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country in 2025 Figure 42. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2032) Figure 44. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country in 2025 Figure 53. South America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 54. South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2032) Figure 55. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country in 2025 Figure 59. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2032) Figure 61. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032) Figure 67. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032) Figure 68. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Unit) by Type (2021-2032) Figure 69. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032) Figure 70. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032) Figure 71. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Unit) by Application (2021-2032) Figure 72. Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Figure 73. Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccines
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • GSK
  • Icosavax
  • Moderna
  • Pfizer
  • RNAimmune
  • Sanofi
  • Advaccine
  • Daiichi Sankyo
  • Immorna
  • Blue Lake Biotechnology
  • Clover Biopharma
  • Innorna
  • Starna Therapeutics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2021-2032)
  4. 2.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032)
  5. 2.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (2021-2032)
  6. 2.3 Respiratory Syncytial Virus Vaccine for the Elderly by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Recombinant Protein Vaccine
  9. 2.3.3 Nucleic Acid Vaccines
  10. 2.3.4 Others
  11. 2.4 Respiratory Syncytial Virus Vaccine for the Elderly by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Centers for Disease Control and Prevention
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units) of Manufacturers (2021-2026)
  3. 3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Product Type & Application
  8. 3.8 Global Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Established Date
  9. 3.9 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 Icosavax
  8. 4.2.1 Icosavax Company Information
  9. 4.2.2 Icosavax Business Overview
  10. 4.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  12. 4.2.5 Icosavax Recent Developments
  13. 4.3 Moderna
  14. 4.3.1 Moderna Company Information
  15. 4.3.2 Moderna Business Overview
  16. 4.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  18. 4.3.5 Moderna Recent Developments
  19. 4.4 Pfizer
  20. 4.4.1 Pfizer Company Information
  21. 4.4.2 Pfizer Business Overview
  22. 4.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  24. 4.4.5 Pfizer Recent Developments
  25. 4.5 RNAimmune
  26. 4.5.1 RNAimmune Company Information
  27. 4.5.2 RNAimmune Business Overview
  28. 4.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  30. 4.5.5 RNAimmune Recent Developments
  31. 4.6 Sanofi
  32. 4.6.1 Sanofi Company Information
  33. 4.6.2 Sanofi Business Overview
  34. 4.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  36. 4.6.5 Sanofi Recent Developments
  37. 4.7 Advaccine
  38. 4.7.1 Advaccine Company Information
  39. 4.7.2 Advaccine Business Overview
  40. 4.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  42. 4.7.5 Advaccine Recent Developments
  43. 4.8 Daiichi Sankyo
  44. 4.8.1 Daiichi Sankyo Company Information
  45. 4.8.2 Daiichi Sankyo Business Overview
  46. 4.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  48. 4.8.5 Daiichi Sankyo Recent Developments
  49. 4.9 Immorna
  50. 4.9.1 Immorna Company Information
  51. 4.9.2 Immorna Business Overview
  52. 4.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  54. 4.9.5 Immorna Recent Developments
  55. 4.10 Blue Lake Biotechnology
  56. 4.10.1 Blue Lake Biotechnology Company Information
  57. 4.10.2 Blue Lake Biotechnology Business Overview
  58. 4.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  60. 4.10.5 Blue Lake Biotechnology Recent Developments
  61. 4.11 Clover Biopharma
  62. 4.11.1 Clover Biopharma Company Information
  63. 4.11.2 Clover Biopharma Business Overview
  64. 4.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  66. 4.11.5 Clover Biopharma Recent Developments
  67. 4.12 Innorna
  68. 4.12.1 Innorna Company Information
  69. 4.12.2 Innorna Business Overview
  70. 4.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  72. 4.12.5 Innorna Recent Developments
  73. 4.13 Starna Therapeutics
  74. 4.13.1 Starna Therapeutics Company Information
  75. 4.13.2 Starna Therapeutics Business Overview
  76. 4.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  78. 4.13.5 Starna Therapeutics Recent Developments
5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Scenario by Region
  1. 5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021-2032
  3. 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021-2026
  4. 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2027-2032
  5. 5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2021-2032
  6. 5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2021-2026
  7. 5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2027-2032
  8. 5.4 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
  9. 5.4.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  11. 5.4.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
  16. 5.5.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  18. 5.5.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
  41. 5.7.1 South America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  43. 5.7.3 South America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  2. 6.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032) & (Units)
  3. 6.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032)
  4. 6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  5. 6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  2. 7.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032) & (Units)
  3. 7.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032)
  4. 7.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  5. 7.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
  2. 8.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
  5. 8.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
  8. 8.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
9 Global Respiratory Syncytial Virus Vaccine for the Elderly Analyzing Market Dynamics
  1. 9.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
  2. 9.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
  3. 9.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
  4. 9.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst